The simultaneous blockade of PD-1 and VEGF ("cooperativity") by one molecule may produce enhanced antitumor activity with an improved safety profile compared with the co-administration of separate ...

CStone Pharmaceuticals ('CStone', HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies, today announced that the first patient ...

Safety and efficacy of FGFR inhibitors in urothelial carcinoma: A systematic review and meta-analysis. Efficacy and safety of tislelizumab (T) combined with gemcitabine and cisplatin (GC) for patients ...

Researchers from Vicero Inc. have developed a Vincobody platform, which allows for design of novel proprietary VHH antibody fragments that possess the efficacy of dual checkpoint blockade while ...

However, the full potential of PD-1 blockade therapy remains unrealized, as response rates are still low across many cancer types. Interleukin-2 (IL-2)-based immunotherapies hold promise, as they can ...

This study highlights the potential of GDF-15 inhibition as a novel strategy to overcome resistance to PD-1 blockade. Clinically, these results suggest that visugromab could expand treatment options ...

Gut microbiota is a critical factor in determining the efficacy of PD-1/L1 blockade. We aimed to explore the role and mechanism of Sutterella wadsworthensis (S.wadsworthensis) in improving the ...

Q4 2024 Earnings Call Transcript March 4, 2025 Compugen Ltd. misses on earnings expectations. Reported EPS is $-0.07 EPS, ...

MedServe, in collaboration with Memorial Sloan Kettering Cancer Center (MSKCC) and the Africa Research Group for Oncology ...